Corrigendum to: Development of bispecific antibodies in China: overview and prospects [0.03%]
Correction to:中国双特异性抗体研发进展：概览与前景
Jing Zhang,Jizu Yi,Pengfei Zhou
Jing Zhang
[This corrects the article DOI: 10.1093/abt/tbaa011.]. © The Author(s) 2021. Published by Oxford University Press on behalf of Antibody Therapeutics. Al...
Published Erratum
Antibody therapeutics. 2022 Jan 19;5(1):84. DOI:10.1093/abt/tbab029 2022
Sagacious epitope selection for vaccines, and both antibody-based therapeutics and diagnostics: tips from virology and oncology [0.03%]
巧妙选择疫苗及抗体治疗和诊断的表位：来自病毒学和肿瘤学的经验教训
Samuel Ken-En Gan,Ser-Xian Phua,Joshua Yi Yeo
Samuel Ken-En Gan
The target of an antibody plays a significant role in the success of antibody-based therapeutics and diagnostics, and vaccine development. This importance is focused on the target binding site-epitope, where epitope selection as a part of d...
The measurement and control of high-risk host cell proteins for polysorbate degradation in biologics formulation [0.03%]
生物制剂配方中吐温脱变反应高风险宿主细胞蛋白的测定与控制
Xuanwen Li,Fengqiang Wang,Hong Li et al.
Xuanwen Li et al.
Nonionic surfactant polysorbates, including PS-80 and PS-20, are commonly used in the formulation of biotherapeutic products for both preventing surface adsorption and acting as stabilizer against protein aggregation. Trace levels of residu...
Longitudinal waning of mRNA vaccine-induced neutralizing antibodies against SARS-CoV-2 detected by an LFIA rapid test [0.03%]
针对SARS-CoV-2的mRNA疫苗诱导的中和抗体衰减的纵向研究（LFIA快速检测试剂盒检测）
Qiao Wang,Lili Feng,Haohai Zhang et al.
Qiao Wang et al.
Although mRNA vaccines against SARS-CoV-2 were highly efficacious against severe illness and hospitalization, they seem to be less effective in preventing infection months after vaccination, especially with the Delta variant. Breakthrough i...
Augmenting recombinant antibody production in HEK293E cells: optimizing transfection and culture parameters [0.03%]
HEK293E细胞中重组抗体生产的增强：转染和培养参数的优化
Zealyn Shi-Lin Heng,Joshua Yi Yeo,Darius Wen-Shuo Koh et al.
Zealyn Shi-Lin Heng et al.
Background: Optimizing recombinant antibody production is important for cost-effective therapeutics and diagnostics. With impact on commercialization, higher productivity beyond laboratory scales is highly sought, where e...
Novel development strategies and challenges for anti-Her2 antibody-drug conjugates [0.03%]
抗HER2抗体药物偶联物的新进展、机遇与挑战
Xinling Zhang,Andrew C Huang,Fahai Chen et al.
Xinling Zhang et al.
Antibody-drug conjugates (ADCs) combining potent cytotoxicity of small-molecule drugs with the selectivity and excellent pharmacokinetic profile of monoclonal antibody (mAb) are promising therapeutic modalities for a diverse range of cancer...
CellCelector™ as a platform in isolating primary B cells for antibody discovery [0.03%]
用于抗体发现的原代B细胞分离平台CellCelector™技术
Wadim L Matochko,Constantin Nelep,Weihsu C Chen et al.
Wadim L Matochko et al.
The most robust strategy in antibody discovery is the use of immunized animals and the ability to isolate and immortalize immune B-cells to hybridoma for further interrogation. However, capturing the full repertoire of an immunized animal i...
Structural arrangement of the VH and VL domains in the COBRA™ T-cell engaging single-chain diabody [0.03%]
COBRA™ T细胞衔接单链双抗体的VH和VL结构域排列方式分析
Jessica Krakow,Michal Hammel,Ying Zhu et al.
Jessica Krakow et al.
Background: COBRA™ (COnditional Bispecific Redirected Activation) T-cell engagers are designed to target solid tumors as a single polypeptide chain prodrug that becomes activated by proteolysis in the tumor microenvironm...
US FDA-approved therapeutic antibodies with high-concentration formulation: summaries and perspectives [0.03%]
高浓度制剂的美国FDA批准治疗性抗体总结与展望
Shawn Shouye Wang,Yifei Susie Yan,Kin Ho
Shawn Shouye Wang
Thirty four (34) of the total US FDA approved 103 therapeutic antibody drugs, accounts for one third of the total approved mAbs, are formulated with high protein concentration (100 mg/mL or above) which are the focus of this article. The hi...
Anti-tumor efficacy of an MMAE-conjugated antibody targeting cell surface TACE/ADAM17-cleaved Amphiregulin in breast cancer [0.03%]
针对乳腺癌细胞表面TACE/ADAM17裂解的Amphiregulin的MMAE连接抗体的抗肿瘤疗效研究
Kristopher A Lofgren,Sreeja Sreekumar,E Charles Jenkins Jr et al.
Kristopher A Lofgren et al.
Background: The Epidermal Growth Factor Receptor (EGFR) ligand, Amphiregulin (AREG), is a key proliferative effector of estrogen receptor signaling in breast cancer and also plays a role in other malignancies. AREG is a s...